Trial Profile
The role of post-operative cetuximab-based bioradiotherapy in high risk head and neck carcinomas.
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 30 Jun 2016
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- 23 May 2015 New trial record